Similarly, in prostate cancer, the alteration frequency varied from 1.1% in ABCG2 to 2.7% in ABCA2 (Figure 3b), with ABCG2 consistently showing the lowest level of genetic alterations in both cancer types. This evidence concerns the gene ABCA2 and prostate carcinoma.